Takeda Pharmaceutical has built new cell drug manufacturing facility for R & D

▴ takeda-pharmaceutical-expands-capacity-build-cell-medicines
Takeda establishes new cell drug manufacturing facility for research and development to support expansion of next-generation clinical programs

Takeda Pharmaceutical Company Limited in Boston, Massachusetts to expand its capacity to manufacture cell medicine. Announced that it has built a new 24,000 square-foot cell medicine manufacturing facility for R & D within its R & D base. The facility will provide end-to-end R & D capabilities, initially focusing on the oncology area and accelerating our next-generation cell drug development activities while exploring the potential for expansion into other therapeutic areas. Will be.

Dr Chris Arendt, Head of Takeda Oncology Therapeutic Area Unit, said: "We have collaborated with the world's top scientists and innovators to build a highly differentiated cancer immunotherapy pipeline and make a leap forward in the development and discovery of new drug discovery methods and mechanisms of action with curative potential. Three cancer cell therapy programs are in the clinical phase, two more are expected to enter the clinical phase during fiscal 2021, and we are working with a sense of urgency and purpose for our patients. This new facility will help us rapidly expand our manufacturing capacity and enable us to move forward with multiple highly differentiated cell therapy programs at the same time. "

Cell therapy in the area of ​​cancer is a type of immunotherapy that uses genetically engineered immune cells to detect and kill cancer cells. Because cell medicines manipulate living cells, they must be manufactured in a highly controlled environment to maintain cleanliness, consistency, and pollution control. Each cell therapy platform in the oncology area has process-specific requirements for how it is prepared, manufactured, transported, and ultimately administered to patients. Next-generation cell therapies are one of several clinical trial platforms that Takeda is conducting research in the oncology area as part of its focus on immune system redirection. Takeda's diverse cancer immunotherapy program pipeline leverages innate immunity: innovative cell therapy, immune involvement platform, regulation of innate immunity, new underlying immune checkpoint platform, tumours Includes those through lytic viruses.

The newly opened cell drug manufacturing facility for research and development will manufacture cell drugs for clinical evaluation from drug discovery to pivotal phase 2b clinical trials. Compliant with the current Good Manufacturing Practices (cGMP), the facility will meet all the requirements set by US, EU and Japanese regulators for the manufacture of cell medicines and support Takeda's clinical trials worldwide. Designed for. The new facility will enhance Takeda's cell medicine potential and production capacity and help advance multiple next-generation cell therapy platforms and programs in the oncology area. These activities include Nobel laureates Dr Shinya Yamanaka (MD, PhD) (artificial pluripotent stem cells) and Dr Adrian Hayday (PhD) of Gamma Delta Therapeutics. (Gamma Delta T cells), Dr Koji Tamada (MD, PhD) (Armed CAR-T) of Nobel Immun Biotech, Dr Michel Sadelan (MD, PhD) of Memorial Sloan Kettering Cancer Center (Next-Generation CAR), Dr Katie Lesbian Cancer Center, MD Anderson Cancer Center, University of Texas (MD, PhD) (CAR-NK) and other world-class people.

Takeda and MD Anderson are developing a best-in-class allogeneic cell therapy product candidate (TAK-007). This drug is a CD19-targeted chimeric antigen receptor-introduced natural killer (CAR-NK) cell drug that is in the Phase 1/2 trial and has relapsed / refractory non-Hodgkin's lymphoma due to its potential use as an off-the-shelf product. It is being tested in NHL) and chronic lymphocytic leukaemia (CLL) patients. Recently, we have also launched two more Phase 1 trial of Takeda's cell therapy program. These are the next-generation CAR T signalling domains under joint development with the Memorial Sloan Kettering Cancer Center (MSK) as therapeutic agents for relapsed / refractory B-cell cancer 19 (T2) 28z1xx CAR T cells (TAK-940). CAR-T (TAK-102) armed with cytokines and chemokine, which is being jointly developed with Neulimune Biotech as a therapeutic agent for GPC3-expressing solid tumours that have been treated. Under the license agreement between MSK and Takeda, Dr Sadelan and MSK reserve the intellectual property and related rights to the content of this release.

Active and close collaboration between R & D and commercial production is critical to the development and delivery of next-generation cell therapies. Takeda's Cell Therapy Translational Engine (CTTE) connects clinical bridging science, product design, development and manufacturing through R & D and commercialization stages. CTTE centralizes bioengineering, CMC (Chemical, Manufacturing and Quality Control), data management, analytics, clinical and bridging science capabilities in one place, overcoming many of the manufacturing challenges faced in the development of cell therapy. ..

Dr Stefan Wildt, Head of Pharmaceutical Sciences & Translational Engines at Takeda's Cell Therapy Division, said: "Thanks to the close relationships and structure of our cell therapy team, we will quickly apply our knowledge to our diverse portfolio of next-generation cell therapies, including CAR NK, armed CAR-T, and gamma delta T cells. The insights gained in manufacturing and clinical development can be quickly shared between our global research, manufacturing and quality teams. This ability allows for therapies that can transform as much as possible. It is very important for our efforts to reach patients quickly. "

Tags : #TakedaPharmaceuticals #immunotherapy #CellTherpyforCancerTreatment #DrChrisArendt #DrStefanWildt

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024